Jay Rosanelli is the CEO and Co-Founder of Syenex, a biotech developing a platform for in vivo gene therapy delivery. While capital in the gene and cell therapy (CGT) space has grown over the last 5 years, there remain serious bottlenecks in delivery. In this conversation, we discuss what Syenex is building, the future of CGT, and what's next in AI-driven drug discovery and neurotech. Check out what Syenex is building: https://www.syenex.com/ 0:00 Introduction 0:55 Background 4:56 Biotech Capital 11:50 The Delivery Problem 17:37 Platform vs. Therapeutics 24:08 Partnership Model31:28 In-vivo CAR-T 37:49 Economics of Platform 42:08 AI x BIo 48:19 Future of BiotechABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

Michael Koeris is the Director of the Biological Technologies Office at DARPA, where he leads some of America's most cutting-edge biological research programs for defense. In this conversation, we discuss how AI is transforming warfare and what DARPA is doing to prepare for biological threats that may exist in the near future.

In this episode, I sit down with Jeff Coller, a professor at the Johns Hopkins University School of Medicine, about how decades of foundational RNA biology laid the groundwork for mRNA vaccines--and what comes next for medicine.Check out the Coller Lab: http://www.collerlab.org/0:00 Background2:21 Maternal RNA7:12 mRNA Stability 8:35 The 2015 Discovery 25:31 RNA Medicines35:18 Biotechnology 40:28 Biotech Startups46:39 Future of RNA Research ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

In this episode, I talk with John Quain, bioethics fellow at the Icahn School of Medicine and lead bioethicist at Manhattan Genomics. We talk about the ethics behind AI, germline editing, and the next wave of biotechnology. Check out the Manhattan Project: https://manhattangenomics.com/ 0:00 Intro 0:41 Background3:50 Artificial Intelligence 6:30 AGI11:16 AI in Medicine14:07 AI in Academic Science17:26 Germline Editing26:01 Pushback to Germline32:18 Future of Biotech EthicsABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

In this episode, biotech founder Cathy Tie unpacks the realities of building in regulated industries and the promise of gene editing done right. From unicorns and dragons to disease-free babies, we explore the technical, ethical, and economic future of germline correction.Check out the Manhattan Project: https://manhattangenomics.com/ 0:00 Intro 1:16 Ranomics7:53 Deep tech 10:40 Biotech challenges13:10 Locke Bio13:56 DTC Health 19:00 Personalized medicine 19:47 Marketing & Insurance 21:50 Germline Editing 26:30 Ethics of germline 31:06 Jiankui He 33:58 Designer babies 35:14 Cost of Germline 37:17 The Manhattan Project ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

In this episode, I sit down with Aubrey de Grey, one of the leading voices in longevity science, and Benji Leibowitz, founder of Pump Science, to explore two visions of the future: longevity escape velocity and scientific escape velocity. We dive into the biology of aging, the systemic bottlenecks slowing progress, and bold new ideas for accelerating discovery.

Visit the LEV Foundation to learn more about what Aubrey de Grey is building: https://www.levf.org/Follow Pump Science for updates on their work accelerating longevity research: https://pump.science/ Check out Molecule to see how decentralized science is reshaping funding and collaboration: https://molecule.xyz/

In this episode, I talk to Charles Brenner, a leading biochemist and outspoken critic of hype in the longevity field. We discuss why many aging studies in model organisms don’t always translate to humans, the limitations of current NAD-related therapies, and how publication bias harms scientific progress. He also shares what excites him most right now—his lab’s work on citrin deficiency and its potential for treating fatty liver disease and metabolic disorders.Visit the Brenner Lab to learn more about their exciting work: https://www.cityofhope.org/research/riggs-institute/diabetes-and-cancer-metabolism/charles-brenner-lab https://brennerlab.netGoogle Scholar: https://scholar.google.com/citations?hl=en&user=XgEjtucAAAAJ&X: https://x.com/CharlesMBrenner

In this episode, I talk to James Sinka, a YC 3-time founder who believes that biotech on-chain will be the next revolution in funding for academic projects. We discuss the challenges of being a deep-tech founder, the intersection of AI & medicine, and some of the key lessons founders need to learn along the way.

In this episode, biotech founder Cathy Tie unpacks the realities of building in regulated industries and the promise of gene editing done right. From unicorns and dragons to disease-free babies, we explore the technical, ethical, and economic future of germline correction.Check out the Manhattan Project: https://manhattangenomics.com/ ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

In this episode, I talk to Ethan Perlstein, a YC biotech founder who wants to make better drugs and financial incentives for curing rare diseases. We discuss the post-academic collapse in science careers, the financial abandonment of most rare diseases, and how crypto and AI could revolutionize drug development.